Aktienanalyse zu Fulcrum Therapeutics Inc (FULC)FULCFulcrum Therapeutics Inc

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. In addition to its product candidates, the Company has developed a discovery approach to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. It also presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in castration resistant prostate cancer models. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Fulcrum Therapeutics Inc is not a strong buy at the moment. The current price is $3.85, which is close to the lower end of analyst price targets, with BofA recently lowering its target to $3. Additionally, the stock has a year-to-date change of -64.74%, indicating significant underperformance. The main risk is the company's ongoing negative net income, with losses reported at -$26,179,000 for Q2 2026, which raises concerns about its financial sustainability.